Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Avicel is a premier brand of microcrystalline cellulose (MCC) that serves as a critical excipient in the pharmaceutical and food industries. Originally developed and commercialized by FMC Corporation in the early 1960s, the brand transitioned to DuPont and is currently a core part of the Pharma Solutions division of IFF (International Flavors & Fragrances). Avicel products are primarily used as binders, fillers, and disintegrants in oral solid dosage forms, enabling the production of high-quality tablets and capsules through direct compression or wet granulation. The product line is recognized globally for its high purity, consistent performance, and various grades tailored to specific manufacturing needs. As a gold standard in pharmaceutical formulation, Avicel supports the delivery of a wide range of small molecule therapeutics across nearly all therapeutic areas.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Avicel.